Immix Biopharma Investor Presentation Deck
August 2023, 52 slides
  1. Immix Biopharma
  2. Related Decks
  3. Investor Presentation Decks
pioneering personalized therapies for oncology and immunology a my a | Immix Biopharma
disclaimer forward looking statements market data | Immix Biopharma
immix investment highlights teal meaner alfa | Immix Biopharma
potential to disrupt the oncology and immunology categories | Immix Biopharma
first car in amyloidosis a billion market by me donee | Immix Biopharma
only car in exposed multiple myeloma a rapidly growing patient segment | Immix Biopharma
only car in exposed multiple myeloma a rapidly growing patient segment newly diagnosed standard of care refractory exposed a rapidly growing patient segment | Immix Biopharma
is overcoming prolonged and | Immix Biopharma
restricts car adoption car | Immix Biopharma
resolves resolving car | Immix Biopharma
clinical development plan multiple myeloma cart cells we patients a patients dosed | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in soft tissue sarcoma and encouraging efficacy in cancer | Immix Biopharma
pipeline summary | Immix Biopharma
upcoming catalysts ria | Immix Biopharma
genius platform tissue specific platform genius platform | Immix Biopharma
lead cell therapy candidate | Immix Biopharma
next generation car for multiple myeloma and amyloidosis first car generated by the genius platform | Immix Biopharma
entering large markets at a pivotal moment market size why now fierce | Immix Biopharma
lead cell therapy candidate clinical trial data coe | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in light chain amyloidosis lote ret | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma a billion market by my cut we | Immix Biopharma
clinical results demonstrate potential for best in class efficacy safety in multiple myeloma | Immix Biopharma
clinical highlights no across patients outpatient car potential highlight | Immix Biopharma
proportion of patients with increased over time in relapsed refractory multiple myeloma | Immix Biopharma
adverse event profile | Immix Biopharma
adverse event profile market | Immix Biopharma
clinical development plan multiple myeloma cart cells we patients a patients dosed | Immix Biopharma
ongoing clinical study design in multiple myeloma | Immix Biopharma
lead candidate chi | Immix Biopharma
tissue specific therapeutic with normalization technology first targeted oncology micelle to achieve small molecule penetration is | Immix Biopharma
preclinical data provides translational rationale combination rationale | Immix Biopharma
clinical trial and supply agreement with for anti i immix | Immix Biopharma
pancreatic preclinical mouse model outperforms gem pac | Immix Biopharma
lead candidate imminent clinical trial data regret clinic ors | Immix Biopharma
a data tumor shrinkage in of heavily soft tissue sarcoma patients lag mare am sic teer mar | Immix Biopharma
opportunity soft tissue sarcoma remains an unmet medical need | Immix Biopharma
clinical data month in late stage sarcoma well tolerated oat immix | Immix Biopharma
direct path to line therapy in clinical trial plan cold | Immix Biopharma
preclinical candidates | Immix Biopharma
cell therapy platform genius platform | Immix Biopharma
tissue specific platform normalization technology tissue specific platform oncology application biologic confidential air | Immix Biopharma
glut targeted for cancer | Immix Biopharma
preclinical data in breast cancer immix therapies produce rare tumor shrinkage stability | Immix Biopharma
glut targeted for inflammatory bowel disease a | Immix Biopharma
team scientific advisory board ies | Immix Biopharma
world class scientific advisory board health | Immix Biopharma
select leadership caster fuse heath is college of booth | Immix Biopharma
select directors | Immix Biopharma
immix investment highlights teal meaner alfa | Immix Biopharma
appendix | Immix Biopharma
market opportunity oncology | Immix Biopharma
opportunity inflammatory bowel disease market company | Immix Biopharma
See More
Immix Biopharma
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Tumor
Cell therapy
Clinical trial
Solid tumor
Recent decks by Immix Biopharma
Investor Presentation
November 2023
Investor Presentation
October 2023
Investor Presentation
August 2023
Investor Presentation
August 2023
See all presentations by Immix Biopharma (5 decks)
Related decks
BioNTech
Results
November 2021
BioNTech
Results
August 2021
BioNTech
Investor Presentation
August 2022
Mink Therapeutics
IPO
October 2021
BioNTech
Results
May 2021
Genelux
Investor Presentation
July 2023
BioNTech
Results
August 2022
Mink Therapeutics
Investor Day
November 2022
Recent decks by Immix Biopharma
See all presentations (5 decks)
Investor Presentation
November 2023
Investor Presentation
October 2023
Investor Presentation
August 2023
Investor Presentation
August 2023
BioNTech
Results
November 2021
BioNTech
Results
August 2021
BioNTech
Investor Presentation
August 2022
Mink Therapeutics
IPO
October 2021
BioNTech
Results
May 2021
Genelux
Investor Presentation
July 2023
BioNTech
Results
August 2022
Mink Therapeutics
Investor Day
November 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io